Your search returned 5 results.

Results
	1.	Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors: Swain, Sandra M PMID: 24129974 Year: 2013 Citation: Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM DOI: http://dx.doi.org/10.1007/s10549-013-2710-z Add to cart (remove)
	2.	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. MedStar authors: Swain, Sandra M PMID: 25693012 Year: 2015 Citation: New England Journal of Medicine. 372(8):724-34, 2015 Feb 19. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, CLEOPATRA Study Group, Cortes J, Ferrero JM, Heeson S, Kim SB, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM DOI: http://dx.doi.org/10.1056/NEJMoa1413513 Add to cart (remove)
	3.	HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens. MedStar authors: Swain, Sandra M PMID: 27692565 Year: 2017 Citation: Clinical Breast Cancer. 17(1):76-78, 2017 Feb Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Gao JJ, Pohlmann PR, Swain SM, Tan M DOI: https://dx.doi.org/10.1016/j.clbc.2016.08.005 Add to cart (remove)
	4.	Bevacizumab added to neoadjuvant chemotherapy for breast cancer. MedStar authors: Swain, Sandra M PMID: 22276821 Year: 2012 Citation: New England Journal of Medicine. 366(4):310-20, 2012 Jan 26. Institution: Washington Cancer Institute Medline publication type: Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Form of publication: Journal Article All authors: Adams PT, Atkins JN, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Mamounas EP, Margolese RG, Mehta RS, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA DOI: http://dx.doi.org/10.1056/NEJMoa1111097 Add to cart (remove)
	5.	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors: Swain, Sandra M PMID: 34890214 Year: 2022 Citation: Journal of Clinical Oncology. 40(5):438-448, 2022 02 10. Department: Associate Dean for Research Development Medline publication type: Journal Article Form of publication: Journal Article All authors: Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP DOI: https://dx.doi.org/10.1200/JCO.21.00896 Add to cart (remove)

Powered by Koha